Effects of Maitake (Grifola frondosa) glucan in HIV-infected patients (2000)
Mycoscience volume 41, pages293–295 (2000)
The effects of MD-Fraction, a β-glucan extracted from Maitake mushroom (Grifola frondosa), on the health status of individuals suffering from HIV infection were evaluated in a long-term trial. The HIV status of the 35 respondents who participated in the study was followed by monitoring CD4+ cell counts, viral load measure, symptoms of HIV infection, status of secondary disease, and sense of well-being. Twenty patients reported an increase in CD4+ cell counts to 1.4–1.8 times, and 8 patients reported a decrease to 0.8–0.5 times. Viral load was reported to increase in 9 patients and decrease in 10 patients. However, 85% of respondents reported an increased sense of well-being with regard to various symptoms and secondary diseases caused by HIV. These results suggest that Maitake D-Fraction had a positive impact in HIV patients.
Myelodysplastic syndromes (MDS) are characterized by ineffective erythropoiesis with dysplastic bone marrow leading to peripheral cytopenia, risk of infection, and progression to acute myelogenous leukemia.
To evaluate the safety and efficacy of an extract of Ganoderma lucidum that shows the strongest 5α-reductase inhibitory activity among the extracts of 19 edible and medicinal mushrooms by a double-blind, placebo-controlled, randomized and dose-ranging study in men with lower urinary tract symptoms (LUTS).
This study aimed to investigate the protective effects of Cordyceps militaris (C. militaris) against reproductive damage induced by bisphenol A (BPA).
Top Quality Mushroom